Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

LY2140023 – Treatment of Schizophrenia



The most common subtypes of schizophrenia affect people between the ages of 15 and 45 years.


Back to Project Details



Related Projects

Ariflo (Cilomilast) - Oral PDE-IV Inhibitor for
Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV...

Capravirine - Anti-Retroviral Drug
Developed by Pfizer Global Research and Development, capravirine is...

Prexige - COX-2 Inhibitor
Prexige (lumiracoxib) is an innovative COX-2 inhibitor developed by...

Erbitux (Cetuximab)
Erbitux is a chimaeric monoclonal antibody (MAb) that is specific for...

Tarceva - Small Molecule
Tarceva (erlotinib) is an oral anti-cancer drug developed by...

See all projects


Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2011 Net Resources International, a trading division of SPG Media Limited.